[ad_1]
Pfizer, AstraZeneca and Moderna are already announcing in the case of a few dozen volunteers participating in clinical trials which of them have been vaccinated with placebo (a drug that does not contain an active ingredient) and which of them have been vaccinated, writes Infostart .hu.
All coronavirus vaccines were collected. We show you where they are made to work and what development it represents. What seems certain is that you will have to wait at least one more year for a vaccine that can be used widely.
Kate Bingham, head of the UK Vaccine Task Force, told The Guardian the vaccine could arrive before Christmas. As it was told:
The possibilities are small, but not impossible. Efficacy data, authorization and, with them, the vaccine that can be used is more likely to arrive early in the year.
The third phase of the clinical trials involved tens of thousands of people from the manufacturers. The third phase works by vaccinating half of the volunteers with the experimental vaccine and the other half with placebo. Who has been vaccinated is stored in an encrypted computer file. Then manufacturers expect a predetermined number of diseases. When these occurred, it is reported that those affected were injected with a placebo or a vaccine. The vaccine is considered effective if the majority of those infected come from the group vaccinated with placebo.
AstraZeneca shares data on 75 infected patients, Moderna on 53 patients and subsequently 106 patients, and Pfizer on 32 patients, followed by 62, 92 and 120 patients. For a vaccine to be usable, it must be completely safe and at least 50 percent effective.
Several have received the vaccine developed at Nesz Zion, and mass production will also begin during testing.
[ad_2]
